Wolverine Blend
Wolverine Blend (BPC-157 + TB500)
BPC-157
TB500 (Thymosin Beta-4)Blend components — PubChem
Research Hub — Aggregated Studies
MedTech Research Group aggregates published research from peer-reviewed journals, clinical trials, and academic institutions. We do not conduct original research. All studies cited below are the work of their respective authors and institutions. Sources are linked for verification.
This product is designated FOR RESEARCH USE ONLY (RUO). These compounds have not been approved or cleared under 21 U.S.C. § 505 and have not been evaluated by the FDA for safety, efficacy, or labeling for clinical, diagnostic, or therapeutic use in humans or animals.
MedTech Research Group will only fulfill orders to qualified researchers affiliated with accredited academic institutions, licensed research facilities, or organizations with active IRB/IACUC oversight.
Purchaser Restrictions
- Purchaser must be a qualified researcher at an accredited institution or licensed research facility
- This product may not be sold or redistributed to individual consumers, wellness clinics, health food stores, or retail establishments
- Not intended for human or animal consumption, diagnostic use, or therapeutic application
- Institutional affiliation and research purpose will be verified prior to order fulfillment
Distribution is limited to qualified research use in compliance with applicable federal and state law. These products bear the "For Research Use Only" designation per FDA labeling requirements (minimum 10 pt. font). Ref: 21 U.S.C. § 505; FD&C Act § 201(p) (unapproved new drug definition).
| Risk Tier | YELLOW |
| Category | Recovery / Healing |
| Subcategory | Dual-Action Tissue Repair |
| Pharmacological Class | Combination Peptide |
| Subclass | Cytoprotective Agent + Actin-Sequestering Peptide |
| Molecular Type | Lyophilized combination of two peptides: BPC-157 (15 AA) + TB500 (43 AA) |
| Origin | Both synthetic; BPC-157 derived from gastric juice protein, TB500 is synthetic version of endogenous Thymosin Beta 4 |
| Regulatory Status | Research Use Only. Neither component is FDA-approved. |
| Route of Administration | Subcutaneous injection |
| Reconstitution | Lyophilized powder; reconstitute with bacteriostatic water |
| Storage | Refrigerate (2-8°C) |
Description
The Wolverine Blend is a pre-combined formulation containing equal parts BPC-157 and Thymosin Beta 4 (TB500) in a single vial. The name references the Marvel character Wolverine, known for his accelerated healing factor — a fitting metaphor for this combination's intended research application.
The rationale for combining these two peptides is based on their complementary and synergistic mechanisms of action. BPC-157 works primarily through growth factor receptor upregulation (particularly VEGF and its receptors), nitric oxide system modulation, and the FAK-paxillin pathway to accelerate tissue repair, stimulate angiogenesis, and provide cytoprotection. TB500 works through actin cytoskeletal dynamics to promote cell migration, reduces inflammation via NFkB pathway modulation, mobilizes stem and progenitor cells to injury sites, and reduces fibrotic scar formation. By targeting these distinct pathways simultaneously, the combination provides broader biological coverage of the wound healing cascade: TB500 facilitates the migration of repair cells to the injury site and reduces the inflammatory environment, while BPC-157 stimulates the growth factors and blood vessel formation needed for those cells to rebuild tissue.
In practical terms, the Wolverine Blend offers convenience (single reconstitution instead of two separate vials) and ensures consistent ratios between the two peptides. The 5mg/5mg and 10mg/10mg formulations are the most popular configurations. This is the third highest-volume product category in the YPB network, with 514 units generating $51,000 in revenue over the analysis period.
Clinical Context
The Wolverine Blend combines two of the most popular recovery peptides into a single convenient formulation. The mechanistic complementarity between BPC-157 (growth factor upregulation, angiogenesis, nitric oxide modulation) and TB500 (actin dynamics, cell migration, stem cell mobilization) provides broader coverage of the wound healing cascade than either peptide alone. The blend is the third highest-volume product category in the YPB network, reflecting strong demand in the recovery and sports injury research segment.
- All notes from both BPC-157 and TB500 sections apply
- No established human dosing protocols — animal study extrapolations are commonly referenced
- The fixed 1:1 ratio may not be optimal for all research applications; separate vials allow ratio adjustment
- Cost analysis: purchasing the blend is more economical and offers convenience vs. separate vials
Published Research
Published Research & Clinical Data
Peer-reviewed studies and clinical trial data related to Wolverine Blend
All research below is conducted by independent institutions. MedTech Research Group provides these references for informational purposes only.
Research citations are being compiled for this compound.
Check back soon — our team is curating peer-reviewed sources.